Search - tctmd.com

Displaying 1 - 20 of 65

Sort: Relevancy | Date

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

L.A. McKeown

May 10, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

L.A. McKeown

June 08, 2023

News Conference News ISET 2023

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

Caitlin E. Cox

January 20, 2023

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

L.A. McKeown

January 31, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

Caitlin E. Cox

July 30, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Caitlin E. Cox

October 05, 2018

Advertisement

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

Top Endovascular News of 2023

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

FDA’s First Take on New Paclitaxel Concerns in CLI

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

Endo-First Strategy Matches Surgery in Select CLI Patients: Retrospective Data

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content